Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study
Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing tr...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2014-04, Vol.44 (4), p.346-354 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 4 |
| container_start_page | 346 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 44 |
| creator | Yoshida, Tatsuya Niho, Seiji Toda, Mayuko Goto, Koichi Yoh, Kiyotaka Umemura, Shigeki Matsumoto, Shingo Ohmatsu, Hironobu Ohe, Yuichiro |
| description | Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity.
We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (≥60 mg/m²)-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade ≥2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n = 161 [32%]) and non-magnesium preloading group (n = 335 [68%]) during the first cycle and all cycles.
The median number of administered cycles was four in both groups. The incidence of Grade ≥2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106-0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129-0.414 during all cycles).
Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity. |
| doi_str_mv | 10.1093/jjco/hyu004 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_jjco_hyu004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24503028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-4651b771ed7ec2d9a824aba4b62f9ee2ca5820db66a7f5dd514c8aef183f47ee3</originalsourceid><addsrcrecordid>eNo9kEtLAzEURoMotlZX7iV7GZvXZFJ3UuoDCrrQ9ZBJbtqUzoMkI86_d0qrq3sXh8PHQeiWkgdKFny-25l2vh16QsQZmlIh84xLRs_RlHCpMqYonaCrGHeEkFyJ4hJNmMgJJ0xNkf0IbQKT_DdgcG78cOtwrTcNRN_XuAuwb7X1zQa3DTY-dnudfJP5xvYGLG6g246G9scbn4ZHrHGAFNrYnZwx9Xa4RhdO7yPcnO4MfT2vPpev2fr95W35tM6MoDJl43JaFQUFW4BhdqEVE7rSopLMLQCY0blixFZS6sLl1uZUGKXBUcWdKAD4DN0fvWZcEAO4sgu-1mEoKSkPrcpDq_LYaqTvjnTXVzXYf_YvDv8FF1hqBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yoshida, Tatsuya ; Niho, Seiji ; Toda, Mayuko ; Goto, Koichi ; Yoh, Kiyotaka ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro</creator><creatorcontrib>Yoshida, Tatsuya ; Niho, Seiji ; Toda, Mayuko ; Goto, Koichi ; Yoh, Kiyotaka ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro</creatorcontrib><description>Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity.
We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (≥60 mg/m²)-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade ≥2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n = 161 [32%]) and non-magnesium preloading group (n = 335 [68%]) during the first cycle and all cycles.
The median number of administered cycles was four in both groups. The incidence of Grade ≥2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106-0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129-0.414 during all cycles).
Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity.</description><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyu004</identifier><identifier>PMID: 24503028</identifier><language>eng</language><publisher>England</publisher><subject>Acute Kidney Injury - blood ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - physiopathology ; Acute Kidney Injury - prevention & control ; Adult ; Aged ; Analysis of Variance ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Biomarkers - blood ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Creatinine - blood ; Drug Administration Schedule ; Female ; Fluid Therapy ; Humans ; Incidence ; Kidney - drug effects ; Kidney - pathology ; Kidney - physiopathology ; Magnesium - administration & dosage ; Magnesium - blood ; Male ; Middle Aged ; Odds Ratio ; Primary Prevention - methods ; Protective Agents - administration & dosage ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Japanese journal of clinical oncology, 2014-04, Vol.44 (4), p.346-354</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-4651b771ed7ec2d9a824aba4b62f9ee2ca5820db66a7f5dd514c8aef183f47ee3</citedby><cites>FETCH-LOGICAL-c416t-4651b771ed7ec2d9a824aba4b62f9ee2ca5820db66a7f5dd514c8aef183f47ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24503028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Toda, Mayuko</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Umemura, Shigeki</creatorcontrib><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><title>Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity.
We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (≥60 mg/m²)-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade ≥2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n = 161 [32%]) and non-magnesium preloading group (n = 335 [68%]) during the first cycle and all cycles.
The median number of administered cycles was four in both groups. The incidence of Grade ≥2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106-0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129-0.414 during all cycles).
Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity.</description><subject>Acute Kidney Injury - blood</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - physiopathology</subject><subject>Acute Kidney Injury - prevention & control</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biomarkers - blood</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Creatinine - blood</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluid Therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Kidney - physiopathology</subject><subject>Magnesium - administration & dosage</subject><subject>Magnesium - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Primary Prevention - methods</subject><subject>Protective Agents - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEURoMotlZX7iV7GZvXZFJ3UuoDCrrQ9ZBJbtqUzoMkI86_d0qrq3sXh8PHQeiWkgdKFny-25l2vh16QsQZmlIh84xLRs_RlHCpMqYonaCrGHeEkFyJ4hJNmMgJJ0xNkf0IbQKT_DdgcG78cOtwrTcNRN_XuAuwb7X1zQa3DTY-dnudfJP5xvYGLG6g246G9scbn4ZHrHGAFNrYnZwx9Xa4RhdO7yPcnO4MfT2vPpev2fr95W35tM6MoDJl43JaFQUFW4BhdqEVE7rSopLMLQCY0blixFZS6sLl1uZUGKXBUcWdKAD4DN0fvWZcEAO4sgu-1mEoKSkPrcpDq_LYaqTvjnTXVzXYf_YvDv8FF1hqBg</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Yoshida, Tatsuya</creator><creator>Niho, Seiji</creator><creator>Toda, Mayuko</creator><creator>Goto, Koichi</creator><creator>Yoh, Kiyotaka</creator><creator>Umemura, Shigeki</creator><creator>Matsumoto, Shingo</creator><creator>Ohmatsu, Hironobu</creator><creator>Ohe, Yuichiro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20140401</creationdate><title>Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study</title><author>Yoshida, Tatsuya ; Niho, Seiji ; Toda, Mayuko ; Goto, Koichi ; Yoh, Kiyotaka ; Umemura, Shigeki ; Matsumoto, Shingo ; Ohmatsu, Hironobu ; Ohe, Yuichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-4651b771ed7ec2d9a824aba4b62f9ee2ca5820db66a7f5dd514c8aef183f47ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acute Kidney Injury - blood</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - physiopathology</topic><topic>Acute Kidney Injury - prevention & control</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biomarkers - blood</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Creatinine - blood</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluid Therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Kidney - physiopathology</topic><topic>Magnesium - administration & dosage</topic><topic>Magnesium - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Primary Prevention - methods</topic><topic>Protective Agents - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Toda, Mayuko</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Yoh, Kiyotaka</creatorcontrib><creatorcontrib>Umemura, Shigeki</creatorcontrib><creatorcontrib>Matsumoto, Shingo</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshida, Tatsuya</au><au>Niho, Seiji</au><au>Toda, Mayuko</au><au>Goto, Koichi</au><au>Yoh, Kiyotaka</au><au>Umemura, Shigeki</au><au>Matsumoto, Shingo</au><au>Ohmatsu, Hironobu</au><au>Ohe, Yuichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>44</volume><issue>4</issue><spage>346</spage><epage>354</epage><pages>346-354</pages><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity.
We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (≥60 mg/m²)-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade ≥2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n = 161 [32%]) and non-magnesium preloading group (n = 335 [68%]) during the first cycle and all cycles.
The median number of administered cycles was four in both groups. The incidence of Grade ≥2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106-0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129-0.414 during all cycles).
Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity.</abstract><cop>England</cop><pmid>24503028</pmid><doi>10.1093/jjco/hyu004</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0368-2811 |
| ispartof | Japanese journal of clinical oncology, 2014-04, Vol.44 (4), p.346-354 |
| issn | 0368-2811 1465-3621 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_jjco_hyu004 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Acute Kidney Injury - blood Acute Kidney Injury - chemically induced Acute Kidney Injury - physiopathology Acute Kidney Injury - prevention & control Adult Aged Analysis of Variance Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biomarkers - blood Cisplatin - administration & dosage Cisplatin - adverse effects Creatinine - blood Drug Administration Schedule Female Fluid Therapy Humans Incidence Kidney - drug effects Kidney - pathology Kidney - physiopathology Magnesium - administration & dosage Magnesium - blood Male Middle Aged Odds Ratio Primary Prevention - methods Protective Agents - administration & dosage Retrospective Studies Severity of Illness Index Treatment Outcome |
| title | Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T16%3A42%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20effect%20of%20magnesium%20preloading%20on%20cisplatin-induced%20nephrotoxicity:%20a%20retrospective%20study&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Yoshida,%20Tatsuya&rft.date=2014-04-01&rft.volume=44&rft.issue=4&rft.spage=346&rft.epage=354&rft.pages=346-354&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyu004&rft_dat=%3Cpubmed_cross%3E24503028%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24503028&rfr_iscdi=true |